Geovax Labs (GOVX)

$0.45 -0.02 (-3.82%)
Market Cap 13.40M
Revenue (ttm) 3.95M
Net Income (ttm) -24.99M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -632.66%
Debt to Equity Ratio 0.00
Volume 558,400
Avg Vol 856,484
Day's Range N/A - N/A
Shares Out 29.71M
Stochastic %K 23%
Beta 3.34
Analysts Strong Sell
Price Target $10.38

Company Profile

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. The company is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tu...

Industry: Biotechnology
Sector: Healthcare
Phone: 678 384 7220
Fax: 678 384 7281
Address:
1900 Lake Park Drive, Suite 380, Smyrna, United States
DeezNuttz
DeezNuttz Nov. 14 at 6:40 PM
$GOVX
0 · Reply
Channelchek
Channelchek Nov. 14 at 5:05 PM
Noble Capital Markets Research Report: GeoVax Labs ($GOVX) – 3Q25 Reported With Clinical Trial Updates and Plans To Move Products Forward Plans For MVA Vaccine and Gedeptin Trial Expectations Confirmed. GeoVax reported a 3Q25 loss of $6.3 million or $(0.31) per share, a smaller loss than the $8.0 million loss we had projected. The company reviewed several developments related to the Geo-MVA vaccine for smallpox/Mpox, Gedeptin, and CM04S1. Discussions for possible marketing collaborations continue. The cash balance on September 30, 2025 was $5.0 million. Read more: https://www.channelchek.com/news-channel/geovax-labs-govx-3q25-reported-with-clinical-trial-updates-and-plans-to-move-products-forward
0 · Reply
To_De_Moon
To_De_Moon Nov. 14 at 4:58 PM
$GOVX change name to shittyvax
0 · Reply
Beanie_Mojo
Beanie_Mojo Nov. 14 at 2:15 PM
$GOVX $HOLO $KLTO all stocks are falling apart - down under 😐
0 · Reply
ZacksResearch
ZacksResearch Nov. 14 at 2:15 PM
$GOVX slipped 5% in after-hours trading post-Q3 earnings ⚠️ ❌ Loss of $0.31 vs. est. $0.24 ❌ No revenues recorded (no marketed products) But the quarter wasn’t without progress — the company highlighted: ✔️ Acceleration of its GEO-MVA mpox/smallpox vaccine program ✔️ Strong clinical data from its GEO-CM04S1 multi-antigen COVID vaccine in immunocompromised patients ✔️ Expansion of Gedeptin into new solid tumor programs Check the upside Wall Street expects 👇 https://www.zacks.com/stock/research/GOVX/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-teaser-21014&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_TEASER_21014
1 · Reply
TopRunners
TopRunners Nov. 14 at 11:09 AM
What is happening to ticker ARBB ?! Looks like they are going to Squeeze ticker ARBB up .. ARBB is starting to breakout! Are they pumping up ticker ARBB for 300% today!? Its insane what's going on in this market.. Looks like all eyes are going to ARBB now.. Trending #1 Watching: $TNXP $IXHL $ABVE $GOVX ::
0 · Reply
TopRunners
TopRunners Nov. 14 at 9:37 AM
Ticker ARBB is making a move.. Could ARBB be todays big squeeze?! 700k shares float.. watchers on ARBB are growing very fast. Would not be surprised if ARBB is todays big runner. 8$+ break could send her parabolic! $TNXP $GOVX $SBET $BMNR ><
0 · Reply
luckysupernova
luckysupernova Nov. 14 at 1:57 AM
$GOVX hope yall voted no. Let them turn the lights off.
2 · Reply
SmilerJon
SmilerJon Nov. 13 at 11:17 PM
$GOVX I have shares in a company but won’t mention who for obvious reasons but they RS time and time again. The last time they were under a dollar and wanted to RS yet again they didn’t get the votes to do the RS. The stock then went over a dollar and has been staying over that for a while now. (Although buying orders are suspended for a while now for some reason). Makes you wonder about the a company and manifesting the stock themselves doesn’t it. I don’t believe it’s a coincidence but maybe I’m totally wrong
1 · Reply
mendez628
mendez628 Nov. 13 at 10:22 PM
$GOVX everyone should be in fuckin prison
1 · Reply
Latest News on GOVX
GeoVax Labs, Inc. (GOVX) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 10:41 PM EST - 3 days ago

GeoVax Labs, Inc. (GOVX) Q3 2025 Earnings Call Transcript

GeoVax Labs, Inc. (GOVX) Q2 2025 Earnings Call Transcript

Jul 28, 2025, 7:43 PM EDT - 3 months ago

GeoVax Labs, Inc. (GOVX) Q2 2025 Earnings Call Transcript

GeoVax Labs, Inc. (GOVX) Q1 2025 Earnings Call Transcript

May 1, 2025, 8:58 PM EDT - 7 months ago

GeoVax Labs, Inc. (GOVX) Q1 2025 Earnings Call Transcript

GeoVax Labs, Inc. (GOVX) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 8:53 PM EDT - 8 months ago

GeoVax Labs, Inc. (GOVX) Q4 2024 Earnings Call Transcript

GeoVax Receives Notice of Allowance For Cancer Vaccine Patent

Dec 9, 2024, 9:00 AM EST - 1 year ago

GeoVax Receives Notice of Allowance For Cancer Vaccine Patent

GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference

Nov 26, 2024, 9:00 AM EST - 1 year ago

GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference

GeoVax Labs, Inc. (GOVX) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 11:33 PM EST - 1 year ago

GeoVax Labs, Inc. (GOVX) Q3 2024 Earnings Call Transcript

GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 12, 2024, 4:00 PM EST - 1 year ago

GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update

GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024

Nov 5, 2024, 9:00 AM EST - 1 year ago

GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024

GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Oct 2, 2024, 9:00 AM EDT - 1 year ago

GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

GeoVax to Participate in Upcoming Investor Conferences in September

Sep 3, 2024, 9:00 AM EDT - 1 year ago

GeoVax to Participate in Upcoming Investor Conferences in September

GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-Market

Aug 28, 2024, 8:59 PM EDT - 1 year ago

GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-Market

GeoVax's stock slides 20% after company raises $8.5 million in stock sale

Aug 20, 2024, 8:09 AM EDT - 1 year ago

GeoVax's stock slides 20% after company raises $8.5 million in stock sale

GeoVax to Raise Approximately $8.5 Million of Gross Proceeds in Offering Priced Above-the-Market

Aug 20, 2024, 7:45 AM EDT - 1 year ago

GeoVax to Raise Approximately $8.5 Million of Gross Proceeds in Offering Priced Above-the-Market

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

Aug 20, 2024, 7:00 AM EDT - 1 year ago

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

CIA CVKD ELUT EUDA GDTC GOSS IMRN

GeoVax's stock soars 54% to lead rally in companies developing mpox treatments

Aug 19, 2024, 7:30 AM EDT - 1 year ago

GeoVax's stock soars 54% to lead rally in companies developing mpox treatments

GeoVax to Present at the Emerging Growth Conference on August 21, 2024

Aug 15, 2024, 9:00 AM EDT - 1 year ago

GeoVax to Present at the Emerging Growth Conference on August 21, 2024

Mpox outbreak: 5 stocks to watch out for as the emergency unfolds

Aug 15, 2024, 8:36 AM EDT - 1 year ago

Mpox outbreak: 5 stocks to watch out for as the emergency unfolds

EBS SIGA

GeoVax Labs, Inc. (GOVX) Q2 2024 Earnings Call Transcript

Aug 10, 2024, 6:15 AM EDT - 1 year ago

GeoVax Labs, Inc. (GOVX) Q2 2024 Earnings Call Transcript

GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board

Aug 8, 2024, 9:00 AM EDT - 1 year ago

GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board

GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 6, 2024, 4:00 PM EDT - 1 year ago

GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update

Update: GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review

Jul 31, 2024, 10:15 AM EDT - 1 year ago

Update: GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review

GeoVax Labs, Inc. (GOVX) Q1 2024 Earnings Call Transcript

May 14, 2024, 8:01 PM EDT - 1 year ago

GeoVax Labs, Inc. (GOVX) Q1 2024 Earnings Call Transcript

GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine

Apr 4, 2024, 12:30 PM EDT - 1 year ago

GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine

GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress

Mar 28, 2024, 9:00 AM EDT - 1 year ago

GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress

GeoVax to Present at the 36th Annual Roth Conference

Mar 12, 2024, 9:00 AM EDT - 1 year ago

GeoVax to Present at the 36th Annual Roth Conference

GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System

Mar 6, 2024, 9:00 AM EST - 1 year ago

GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System

GeoVax Labs, Inc. (GOVX) Q4 2023 Earnings Call Transcript

Mar 1, 2024, 2:34 AM EST - 1 year ago

GeoVax Labs, Inc. (GOVX) Q4 2023 Earnings Call Transcript

GeoVax Reports 2023 Year-End Financial Results and Provides Business Update

Feb 29, 2024, 4:00 PM EST - 1 year ago

GeoVax Reports 2023 Year-End Financial Results and Provides Business Update

GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024

Feb 22, 2024, 9:00 AM EST - 1 year ago

GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024

GeoVax to Present at the 2024 BIO CEO & Investor Conference

Feb 19, 2024, 9:00 AM EST - 1 year ago

GeoVax to Present at the 2024 BIO CEO & Investor Conference

GeoVax Announces Multiple Patent Issuances and Allowances

Feb 13, 2024, 9:00 AM EST - 1 year ago

GeoVax Announces Multiple Patent Issuances and Allowances

GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster

Feb 6, 2024, 9:00 AM EST - 1 year ago

GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster

GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement

Jan 29, 2024, 9:00 AM EST - 1 year ago

GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement

GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology

Jan 8, 2024, 9:00 AM EST - 2 years ago

GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology

GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients

Jan 4, 2024, 9:00 AM EST - 2 years ago

GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients

GeoVax Announces Issuance of Malaria Vaccine Patent

Jan 3, 2024, 9:00 AM EST - 2 years ago

GeoVax Announces Issuance of Malaria Vaccine Patent

GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024

Dec 27, 2023, 9:00 AM EST - 2 years ago

GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024

GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox

Dec 19, 2023, 9:00 AM EST - 2 years ago

GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox

GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress

Nov 30, 2023, 4:30 PM EST - 2 years ago

GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress

GeoVax to Participate in Upcoming December Investor Events

Nov 29, 2023, 9:00 AM EST - 2 years ago

GeoVax to Participate in Upcoming December Investor Events

GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress

Nov 28, 2023, 9:00 AM EST - 2 years ago

GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress

Progress on GeoVax's Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023

Nov 14, 2023, 9:00 AM EST - 2 years ago

Progress on GeoVax's Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023

GeoVax Labs, Inc. (GOVX) Q3 2023 Earnings Call Transcript

Nov 8, 2023, 9:26 PM EST - 2 years ago

GeoVax Labs, Inc. (GOVX) Q3 2023 Earnings Call Transcript

GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 8, 2023, 4:00 PM EST - 2 years ago

GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update

GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine

Oct 30, 2023, 9:00 AM EDT - 2 years ago

GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine

GeoVax to Participate in Upcoming November Investor and Industry Events

Oct 25, 2023, 9:00 AM EDT - 2 years ago

GeoVax to Participate in Upcoming November Investor and Industry Events

GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities

Oct 24, 2023, 9:00 AM EDT - 2 years ago

GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities

GeoVax Receives Notice of Allowance for Marburg Vaccine Patent

Oct 9, 2023, 9:00 AM EDT - 2 years ago

GeoVax Receives Notice of Allowance for Marburg Vaccine Patent

GeoVax Receives Notice of Allowance for HIV Vaccine Patent

Oct 5, 2023, 9:00 AM EDT - 2 years ago

GeoVax Receives Notice of Allowance for HIV Vaccine Patent

DeezNuttz
DeezNuttz Nov. 14 at 6:40 PM
$GOVX
0 · Reply
Channelchek
Channelchek Nov. 14 at 5:05 PM
Noble Capital Markets Research Report: GeoVax Labs ($GOVX) – 3Q25 Reported With Clinical Trial Updates and Plans To Move Products Forward Plans For MVA Vaccine and Gedeptin Trial Expectations Confirmed. GeoVax reported a 3Q25 loss of $6.3 million or $(0.31) per share, a smaller loss than the $8.0 million loss we had projected. The company reviewed several developments related to the Geo-MVA vaccine for smallpox/Mpox, Gedeptin, and CM04S1. Discussions for possible marketing collaborations continue. The cash balance on September 30, 2025 was $5.0 million. Read more: https://www.channelchek.com/news-channel/geovax-labs-govx-3q25-reported-with-clinical-trial-updates-and-plans-to-move-products-forward
0 · Reply
To_De_Moon
To_De_Moon Nov. 14 at 4:58 PM
$GOVX change name to shittyvax
0 · Reply
Beanie_Mojo
Beanie_Mojo Nov. 14 at 2:15 PM
$GOVX $HOLO $KLTO all stocks are falling apart - down under 😐
0 · Reply
ZacksResearch
ZacksResearch Nov. 14 at 2:15 PM
$GOVX slipped 5% in after-hours trading post-Q3 earnings ⚠️ ❌ Loss of $0.31 vs. est. $0.24 ❌ No revenues recorded (no marketed products) But the quarter wasn’t without progress — the company highlighted: ✔️ Acceleration of its GEO-MVA mpox/smallpox vaccine program ✔️ Strong clinical data from its GEO-CM04S1 multi-antigen COVID vaccine in immunocompromised patients ✔️ Expansion of Gedeptin into new solid tumor programs Check the upside Wall Street expects 👇 https://www.zacks.com/stock/research/GOVX/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-teaser-21014&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_TEASER_21014
1 · Reply
TopRunners
TopRunners Nov. 14 at 11:09 AM
What is happening to ticker ARBB ?! Looks like they are going to Squeeze ticker ARBB up .. ARBB is starting to breakout! Are they pumping up ticker ARBB for 300% today!? Its insane what's going on in this market.. Looks like all eyes are going to ARBB now.. Trending #1 Watching: $TNXP $IXHL $ABVE $GOVX ::
0 · Reply
TopRunners
TopRunners Nov. 14 at 9:37 AM
Ticker ARBB is making a move.. Could ARBB be todays big squeeze?! 700k shares float.. watchers on ARBB are growing very fast. Would not be surprised if ARBB is todays big runner. 8$+ break could send her parabolic! $TNXP $GOVX $SBET $BMNR ><
0 · Reply
luckysupernova
luckysupernova Nov. 14 at 1:57 AM
$GOVX hope yall voted no. Let them turn the lights off.
2 · Reply
SmilerJon
SmilerJon Nov. 13 at 11:17 PM
$GOVX I have shares in a company but won’t mention who for obvious reasons but they RS time and time again. The last time they were under a dollar and wanted to RS yet again they didn’t get the votes to do the RS. The stock then went over a dollar and has been staying over that for a while now. (Although buying orders are suspended for a while now for some reason). Makes you wonder about the a company and manifesting the stock themselves doesn’t it. I don’t believe it’s a coincidence but maybe I’m totally wrong
1 · Reply
mendez628
mendez628 Nov. 13 at 10:22 PM
$GOVX everyone should be in fuckin prison
1 · Reply
mendez628
mendez628 Nov. 13 at 9:21 PM
$GOVX how much lower can this shit go
0 · Reply
Ueberschlaefer
Ueberschlaefer Nov. 13 at 9:05 PM
$GOVX i hope they announce they are shutting down, to spare the retail world from further financial predation.
0 · Reply
To_De_Moon
To_De_Moon Nov. 13 at 2:24 PM
$GOVX give some hope with earnings
1 · Reply
juvie22
juvie22 Nov. 13 at 1:17 PM
$GOVX
1 · Reply
bowlerhatsftw
bowlerhatsftw Nov. 12 at 8:36 PM
$GOVX tripple bottom
0 · Reply
To_De_Moon
To_De_Moon Nov. 11 at 8:41 PM
$MRNA $GOVX
0 · Reply
geniuscali
geniuscali Nov. 10 at 4:23 PM
$GOVX why are they wasting $$$ON covid 19. Its over. Money is gonr
1 · Reply
DrewSerick
DrewSerick Nov. 10 at 1:46 AM
Made my month green for sure 🔥 I recommend you FOLLOW @ICEMAN_ALERTS - One of the best traders i know 💎 Always in point with his entries. Check him out Also holding > $TNXP $GOVX $SGBX $RR
0 · Reply
Martian_Paradisee
Martian_Paradisee Nov. 7 at 1:42 AM
$GOVX Is $1 possible tomorrow?
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Nov. 6 at 1:21 AM
Traded $GOVX before along with other small/mid caps. I only buy when H% is low. It takes patience but the results always speak for themselves. I make this to see if the strategy is successful or not.
0 · Reply
Ueberschlaefer
Ueberschlaefer Nov. 5 at 4:04 AM
$GOVX phase 2 -> phase 3 = valley of death. it will take years and money that GOVX doesn't have to ever get there. this business is bankrupt has no future. the most it can do is to take down retail investors in its death throes. the reverse split will not save it. the stock will be shorted instantly by bears from all over the galaxy. we will see this under $1.00 in 2026 again after the degenerate boomer board and shareholders approve the RS.
1 · Reply
luckysupernova
luckysupernova Nov. 5 at 2:46 AM
$GOVX does this mean no mercury?
0 · Reply